ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma

• Published in: Neoplasia (New York, N.Y.) Vol. 23; no. 12; pp. 1227 - 1239
• Main Authors: Huang, Wenbin, Chen, Kunling, Lu, Yishi, Zhang, Donghui, Cheng, Yuan, Li, Liuran, Huang, Weimei, He, Guolin, Liao, Hangyu, Cai, Lei, Tang, Yujun, Zhao, Liang, Pan, Mingxin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2021; Neoplasia Press; Elsevier
• Subjects: ABCC5; Acquired resistance; Amino Acid Transport System y+ - metabolism; Carcinoma, Hepatocellular - metabolism; Carcinoma, Hepatocellular - pathology; Cell Line, Tumor; Drug Resistance, Neoplasm - physiology; Ferroptosis; Ferroptosis - physiology; Hepatocellular carcinoma; Humans; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Multidrug Resistance-Associated Proteins - metabolism; Original article; Sorafenib; Sorafenib - pharmacology; GPx4; IHC; ABCC5; qRT-PCR; Hepatocellular carcinoma; Ferroptosis; HCC; SLC7A11; Acquired resistance; NRF2; Sorafenib; ROS; IF; GSH; 5-Fu

Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), and reducing sorafenib resistance is an important issue to be resolved for the clinical treatment of HCC. In the current study, we identified that ABCC5 is a critical regulator and a promising therapeutic ta...